Kathmere Capital Management’s Thermo Fisher Scientific TMO Stock Holding History

Kathmere Capital Management’s Portfolio TMO Stock Details TMO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$405K	Sell	808 -380	-32%	-$182K	0.02%	451
2026 Q1	$584K	Buy	1,188 +94	+9%	+$51K	0.04%	319
2025 Q4	$634K	Buy	1,094 +162	+17%	+$91.6K	0.04%	269
2025 Q3	$452K	Buy	932 +360	+63%	+$168K	0.03%	311
2025 Q2	$232K	Sell	572 -410	-42%	-$171K	0.02%	418
2025 Q1	$489K	Buy	982 +135	+16%	+$73.1K	0.04%	249
2024 Q4	$441K	Buy	847 +6	+0.7%	+$3.3K	0.04%	255
2024 Q3	$520K	Buy	841 +162	+24%	+$95.9K	0.05%	201
2024 Q2	$375K	Buy	+679	New	+$389K	0.04%	221
2021 Q1	–	Sell	-33	Closed	-$15K	–	377
2020 Q4	$15K	Buy	+33	New	+$15.5K	﹤0.01%	297

Other funds holding TMO

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Kathmere Capital Management's TMO Position: Q2 2026 in Review

Kathmere Capital Management reduced its Thermo Fisher Scientific (TMO) stake by 32% in Q2 2026, selling an estimated $182K and leaving 808 shares worth $405K. The position accounts for 0.02% of the portfolio, ranked #451.

Kathmere Capital Management first reported a position in TMO in Q4 2020 and has held it in 10 quarters since. The position peaked at $634K in Q4 2025. 2,609 funds tracked by Wall St. Rank hold TMO as of Q2 2026.

Kathmere Capital Management held 808 shares of Thermo Fisher Scientific worth $405K as of Q2 2026.
Kathmere Capital Management sold 380 Thermo Fisher Scientific shares in Q2 2026, an estimated $182K.
Thermo Fisher Scientific made up 0.02% of Kathmere Capital Management's portfolio in Q2 2026, its #451 holding.
Kathmere Capital Management first reported a position in Thermo Fisher Scientific in Q4 2020 and has held it in 10 quarters since.
Kathmere Capital Management's Thermo Fisher Scientific position peaked at $634K in Q4 2025.
2,609 funds tracked by Wall St. Rank held Thermo Fisher Scientific as of Q2 2026.

Based on Kathmere Capital Management's 13F filing for Q2 2026, filed 29 Jul 2026.